Revenue
No reported data
enGene Therapeutics Inc. (ENGN)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Research & development | $94.5M | $38.3M | $16.5M | $15.5M |
| Operating expenses | $123.2M | $62.3M | $26.1M | $19.4M |
| Operating income | −$123.2M | −$62.3M | −$26.1M | −$19.4M |
| EBITDAderived | −$122.7M | −$62.0M | −$25.9M | −$19.2M |
| Net income | −$117.3M | −$55.1M | −$99.9M | −$24.5M |
| Basic EPSper diluted share | $2.29 | $1.46 | $151.22 | $44.30 |
| Diluted EPSper diluted share | $2.29 | $1.46 | $151.22 | $44.30 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 30, 2024Form 4 | Forbion Growth Management B.V. +1TenPercentOwner | BuyCommon Shares | 561.8K | $8.90 | $5.00M | 3.03M |
| Oct 8, 2024Form 4 | Forbion Growth Opportunities Fund I Cooperatief U.A. +1TenPercentOwner | BuyCommon Shares | 800 | $6.60 | $5.3K | 2.47M |
| Oct 7, 2024Form 4 | Forbion Growth Opportunities Fund I Cooperatief U.A. +1TenPercentOwner | BuyCommon Shares | 11.8K | $6.55 | $77.6K | 2.47M |
| Oct 4, 2024Form 4 | Forbion Growth Opportunities Fund I Cooperatief U.A. +1TenPercentOwner | BuyCommon Shares | 6.0K | $6.54 | $39.2K | 2.46M |
| Oct 3, 2024Form 4 | Forbion Growth Opportunities Fund I Cooperatief U.A. +1TenPercentOwner | BuyCommon Shares | 5.8K | $6.48 | $37.4K | 2.45M |